Trial reportPloS one2008
Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza.
Trial report in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection.Antimicrobial agents and chemotherapy · 2011Trial
- Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients.Antimicrobial agents and chemotherapy · 2011Trial
- Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.Antimicrobial agents and chemotherapy · 2010Trial
- Influenza and Aging: Clinical Manifestations, Complications, and Treatment Approaches in Older Adults.Drugs & aging · 2025Review
- Bioavailability of Orally Administered Drugs in Critically Ill Patients.Journal of pharmacy practice · 2023Article
- Severe myocarditis due to influenza A(H1N1)pdm09 viral infection in a young woman successfully treated with intravenous zanamivir: A case report.Clinical case reports · 2019Article
- Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series.BMC infectious diseases · 2019Article
- Influenza and the patient with end-stage renal disease.Journal of nephrology · 2018Review
- Peramivir injection in the treatment of acute influenza: a review of the literature.Infection and drug resistance · 2016Review
- How to approach and treat viral infections in ICU patients.BMC infectious diseases · 2014Review
- Seasonal Human Influenza: Treatment Options.Current treatment options in infectious diseases · 2014Review
- Adjuvant efficacy of mOMV against avian influenza virus infection in mice.Journal of microbiology (Seoul, Korea) · 2013Article
- Severe community-acquired pneumonia.Critical care clinics · 2013Review
- Pandemic H1N1 influenza.Journal of thoracic disease · 2011Article
- Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.Antimicrobial agents and chemotherapy · 2011Article
- XIth International Symposium on Respiratory Viral Infections.Influenza and other respiratory viruses · 2011Article
- Pharmacokinetics of oseltamivir according to trimester of pregnancy.American journal of obstetrics and gynecology · 2011Article
- Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses.Antimicrobial agents and chemotherapy · 2011Article
- High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.Antimicrobial agents and chemotherapy · 2011Article
- Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.Clinical pharmacokinetics · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the absence of a parenteral drug, oral oseltamivir is currently recommended by the WHO for treating H5N1 influenza. Whether oseltamivir absorption is adequate in severe influenza is unknown. We measured the steady state, plasma concentrations of nasogastrically administered oseltamivir 150 mg bid and its active metabolite, oseltamivir carboxylate (OC), in three, mechanically ventilated patients with severe H5N1 (male, 30 yrs; pregnant female, 22 yrs) and severe H3N2 (female, 76 yrs). Treatments were started 6, 7 and 8 days after illness onset, respectively. Both females were sampled while on continuous venovenous haemofiltration. Admission and follow up specimens (trachea, nose, throat, rectum, blood) were tested for RNA viral load by reverse transcriptase PCR. In vitro virus susceptibility to OC was measured by a neuraminidase inhibition assay. Admission creatinine clearances were 66 (male, H5N1), 82 (female, H5N1) and 6 (H3N2) ml/min. Corresponding AUC(0-12) values (5932, 10,951 and 34,670 ng.h/ml) and trough OC concentrations (376, 575 and 2730 ng/ml) were higher than previously reported in healthy volunteers; the latter exceeded 545 to 3956 fold the H5N1 IC(50) (0.69 ng/ml) isolated from the H5N1 infected female. Two patients with follow-up respiratory specimens cleared their viruses after 5 (H5N1 male) and 5 (H3N2 female) days of oseltamivir. Both female patients died of respiratory failure; the male survived. 150 mg bid of oseltamivir was well absorbed and converted extensively to OC. Virus was cleared in two patients but two patients died, suggesting viral efficacy but poor clinical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.